Advanced non-small cell lung cancer Cancer
Conditions
Interventions
Patients with stage IIIB to IV or recurrent NSCLC who received AL3818 or AL3818-containing regimens between 01/06/2018 to 30/09/2020 are enrolled in the study. AL3818 is administered orally once daily
Sponsors
Peking University Shenzhen Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age =8 years 2. Pathologically confirmed stage IIIB/IV or recurrent NSCLC 3. Had at least one radiologically measurable disease as assessed using Response Evaluation Criteria in Solid Tumours (RECIST, version 1.1); and they did not receive local treatment such as radiotherapy or interventional therapy for the target lesions during anlotinib treatment
Exclusion criteria
Exclusion criteria: 1. Other pathological types than NSCLC including small cell lung cancer (including mixed with small cell and non-small cell lung cancer) 2. Patients who are diagnosed with malignancies other than NSCLC within the previous 5 years (except those with negligible risk of metastases or death and treated with curative intent, based on primary investigator discretion)
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Data collected from the electronic medical system of Peking University Shenzhen Hospital, assessed every 6 to 12 weeks: 1. Objective response rate (ORR), defined as the percentage of patients with at least one confirmed response before any evidence of progression 2. Disease control rate (DCR), defined as the percentage of patients with at least one confirmed response plus stable disease before any evidence of progression 3. Overall survival (OS), defined as the time from the first administration to death from any cause or last follow-up 4. Toxicity, as categorized and graded according to the NCI-CTCAE | — |
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival (PFS), defined as the time from the first administration to the documented disease progression or death due to any cause, data collected from the electronic medical system of Peking University Shenzhen Hospital, assessed every 6 to 12 weeks | — |
Countries
China
Outcome results
None listed